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Profiling of WDR36 Missense Variants in German
Patients with Glaucoma
Francesca Pasutto,1 Christian Y. Mardin,2 Karin Michels-Rautenstrauss,1
Bernhard H. F. Weber,3 Heinrich Sticht,4 Gabriela Chavarria-Soley,1 Bernd Rautenstrauss,1
Friedrich Kruse,2 and Andre´ Reis1
PURPOSE. Mutations in WDR36 were recently reported in pa-
tients with adult-onset primary open-angle glaucoma (POAG).
In this study, the prevalence of WDR36 variants was investi-
gated in patients with glaucoma who were of German descent
with diverse age of onset and intraocular pressure levels.
METHODS. Recruited were 399 unrelated patients with glau-
coma and 376 healthy subjects of comparable age and origin,
who had had repeated normal findings in ophthalmic exami-
nations. The frequency of observed variants was obtained by
direct sequencing of the entire WDR36 coding region.
RESULTS. A total of 44 WDR36 allelic variants were detected,
including 14 nonsynonymous amino acid alterations, of which
7 are novel (P31T, Y97C, D126N, T403A, H411Y, H411L, and
P487R) and 7 have been reported (L25P, D33E, A163V, H212P,
A449T, D658G and I264V). Of these 14 variants, 6 were clas-
sified as polymorphisms as they were detected in patients and
control individuals at similar frequencies. Eight variants
present in 15 patients (3.7%) but only 1 control individual
(0.2%) were defined as putative disease-causing variants (P 
0.0005). Within this patient group, 12 (80%) presented with
high and 3 (20%) with low intraocular pressure. Disease sever-
ity and age of onset showed a broad range.
CONCLUSIONS. The occurrence of several rare putative disease-
causing variants in patients with glaucoma suggests that
WDR36 may be a minor disease-causing gene in glaucoma, at
least in the German population. The large variability in
WDR36, though, requires functional validation of these vari-
ants, once its function is characterized. (Invest Ophthalmol Vis
Sci. 2008;49:270–274) DOI:10.1167/iovs.07-0500
Glaucoma refers to a group of clinically and geneticallyheterogeneous ophthalmologic disorders leading to visual
impairment and blindness. The characteristic clinical sign is
cupping of the optic nerve head with subsequent retinal nerve
fibers loss, usually associated with elevated intraocular pres-
sure. The disease affects more than 67 million people world-
wide.1 Epidemiologic studies have repeatedly confirmed that
primary open-angle glaucoma (POAG), the most common adult
form of the disease, is one of the main causes of blindness (8%)
in European populations.2,3 The age of onset of glaucoma
manifestation ranges from birth to late adulthood. Affected
individuals are usually asymptomatic until the late stages of
disease, when significant and irreversible optic nerve degener-
ation has already occurred.4 As glaucoma-related visual loss is
preventable in many cases and as the sensitivity of current
diagnostic methods is suboptimal, there is an urgent need to
diagnose glaucoma in its early stages.5,6 Identification of the
genes involved in the etiology of glaucoma provides a signifi-
cant opportunity for presymptomatic diagnosis, improved
prognosis, and better understanding of the etiology of this
blinding condition.
Although many cases are sporadic, POAG shows familial
clustering consistent with autosomal dominant inheritance and
incomplete penetrance. Reduced penetrance and excess of
sporadic cases is particularly seen in late-onset forms. Never-
theless, more than 11 (GLC1A-GLC1M) different POAG loci
have been mapped so far.7–12 During the past decade, two
genes have been reported for POAG: myocilin (MYOC) on
chromosome 1, long-arm region q24.3-q25.2, primarily mu-
tated in juvenile-onset patients,13 and optineurin (OPTN) on
chromosome 10, short-arm region p14-p15, mainly mutated in
individuals with normal-tension glaucoma (NTG).14,15 Al-
though investigators in several studies have consistently found
mutations inMYOC in approximately 3% of cases including the
German population (3.2%),16 mutations in OPTN seem to be a
rather infrequent cause of POAG or NTG.17,18 In a recent
study, a new POAG locus was identified on chromosome 5,
region q22.1 (designated as GLC1G). Screening of the WD40-
repeat 36 gene (WDR36) in 130 patients with an adult-onset
form of glaucoma with high and low pressure identified muta-
tions in approximately 5% of patients. Both familial and spo-
radic cases were affected.19
WD40-repeats are stretches of 40 amino acids that contain
tryptophan (W) and aspartic acid (D). WD-repeat–containing
proteins comprise a large family found in all eukaryotes and are
implicated in a variety of functions ranging from signal trans-
duction and transcription regulation to cell cycle control and
apoptosis. The underlying common function of all WD-repeat
proteins is coordinating multiprotein complex assemblies,
where the repeating units serve as a rigid scaffold for protein
interactions. Based on sequence similarity, WDR36 was pro-
posed to contain five20 to eight19 WD40 repeats. In addition,
WDR36 contains a C-terminal UTP21 domain that is specifically
associated with WD40 repeats21 as well as sequence stretches
that are characteristic for AMP-binding or which exhibit struc-
tural similarity to the C-terminal part of cytochrome cd119
Expression of WDR36 was shown in human ocular and non-
ocular tissues as well as in embryonic and adult mouse tis-
sues.19 It has been suggested that WDR36 may be involved in
T-cell activation20 and recently, T-cell-mediated responses have
been hypothesized to participate in glaucoma-associated optic
nerve degeneration.22 However, the exact physiological func-
tion of the protein and its role in glaucoma pathogenesis
remain unclear. The purpose of this study was to determine the
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prevalence of WDR36 sequence variants in a well-character-
ized group of 399 unrelated German patients with POAG, NTG,
or juvenile open-angle glaucoma (JOAG).
MATERIAL AND METHODS
Patients and Control Subjects
The study was approved by the ethics review board of the Medical
Faculty of the University of Erlangen-Nuremberg and was in accor-
dance with the tenets of the Declaration of Helsinki. All subjects gave
informed consent before entering the study.
The group of patients with glaucoma consisted of 399 subjects of
German (European) origin: 270 had primary open-angle glaucoma
(high-pressure POAG), 47 had juvenile open-angle glaucoma (JOAG),
and 82 had normal-tension open-angle glaucoma (NTG). All individuals
underwent standardized clinical examinations for glaucoma at the
Ophthalmologic Department of the University of Erlangen-Nuremberg,
Erlangen. These comprised slitlamp biomicroscopy, gonioscopy, auto-
mated visual field testing (Octopus G1; Interzeag, Schlieren, Switzer-
land), fundus photography (Carl Zeiss Meditec, Oberkochen, Ger-
many), optional laser scanning tomography (HRT I and II; Heidelberg
Engineering, Heidelberg, Germany) of the disc and a 24-hour Gold-
mann-applanation intraocular pressure (IOP) tonometry profile with
five measurements. Manifest high-tension POAG was defined as the
presence of glaucomatous optic disc damage (in at least one eye),
visual field defects in at least one eye, and intraocular pressure higher
than 21 mm Hg in one eye without therapy. Causes of secondary
glaucoma, such as primary melanin dispersion and pseudoexfoliation,
were excluded. Glaucomatous optic nerve damage was defined as focal
loss of neuroretinal rim or nerve fiber layer associated with a specific
visual field defect. According to Jonas, stage 0 optic disc was defined
as normal, stage I with vertical elongation of the cup and neuroretinal
rim loss at the 12 and 6 o’clock positions, stage II with focal rim loss,
stage III and IV with advanced rim loss, and stage V, as absolute optic
disc atrophy. Disc area was measured with HRT or estimated with a
Goldmann lens and slitlamp (Haag-Streit, Ko¨niz, Switzerland).23 A
pathologic visual field was defined by a pathologic Bebie curve, three
adjacent test points with more than 5 dB sensitivity loss or at least one
point with a more than 15-dB loss. Patients who showed glaucomatous
changes of the optic disc and visual field but no IOP elevation over 21
mm Hg after a 24-hour IOP-measurement (sitting and supine body
position) without therapy received a diagnosis of NTG. Patients were
classified as having JOAG when age at onset in the index case was
below 40 years and no other ocular reason for open-angle glaucoma
was visible. In total, 178 (44.4%) patients had a family history of
glaucoma. All patients were also screened for myocilin mutations, as
determined by direct sequencing of all coding regions of MYOC.
Mutations were identified in 18 (4.5%) patients also included in the
present study, of whom one carried aWDR36 variant (described later).
Detailed results on MYOC screening will be described elsewhere (Pa-
sutto et al., manuscript in preparation). A subset of 96 patients tested
with the same methods was negative for OPTN mutations. As OPTN
mutations are very rare, the entire cohort was not screened.
The 376 control subjects were all of German origin and were
recruited from the same geographic regions as the patients. In addi-
tion, the age- and sex-matched control subjects underwent ophthalmic
examination. Thus, at the time of examination and inclusion in this
study the age ranged from 51 to 92 years (mean, 73.9  6.4). They had
IOP below 20 mm Hg, no glaucomatous disc damage, and no family
history of glaucoma. Visual acuity was at least 0.8, and the media were
clear for examination.
Mutation Screening
Genomic DNA was prepared from peripheral blood samples by a
standard salting-out protocol. Individual coding exons of the WDR36
gene including flanking intronic/untranslated region (UTR) sequences
were amplified by polymerase chain reaction (PCR) by the appropriate
amplification protocols. Primer sequences were selected with Primer3
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi/)
and are available on request. Purified PCR fragments were sequenced (Big
Dye Termination chemistry ver. 3.1; Applied Biosystems, Weiterstadt,
Germany) on a capillary automated sequencer (model 3730 Genetic An-
alyzer; Applied Biosystems). Each variant was confirmed by a second
independent analysis. GenBank Accession NM_139281 was used as cDNA
reference sequence and NT_034772 as genomic reference sequence
(http://www.ncbi.nlm.nih.gov/ National Center for Biotechnology In-
formation, Bethesda, MD). We used Q8NI36 (WD36_HUMAN) from
the Swiss-Prot/Trembl database (http://www.sanger.ac.uk, Sanger
Centre, Hinxton, UK) as the reference protein sequence. Evolutionary
conservation of nonsynonymous variants was investigated with protein
sequence alignment generated by ClustalW (http://www.ebi.ac.uk/
clustalw/ European Molecular Biology Laboratory, Heidelberg, Ger-
many) and compared with that presented by the Ensembl Database
(http://www.ensembl.org).24
RESULTS
Direct sequence analysis of WDR36 in 399 unrelated patients
with glaucoma identified 44 allelic variants, 14 of which cause
amino acid substitution (Table 1). Seven of these are novel
(P31T, Y97C, D126N, T403A, H411Y, H411L, and P487R),
whereas six variants (L25P, D33E, A163V, H212P, A449T, and
D658G) have been reported.19,25
These nonsynonymous variants are located in the amino-
terminal region, as well as in the WD-40 repeat domains (Fig.
1A). The latter mostly affect positions evolutionary conserved
among orthologous in mouse, rat, zebra fish, and puffer fish
(Fig. 1B). Variations L25P, P31T, and D33E could not be un-
ambiguously aligned because of the lack of sequence conser-
vation of the N-terminal region.
Mutations that were defined as disease-causing19 were
found in 1.8% (7/399) of the patients and in 2.1% (8/376) of the
control individuals. Sequence variants reported to be potential
disease-susceptibility mutations19 were detected in 4.7% (19/
399) of the patients and 4.8% (18/376) of control subjects
(Table 1). One variant that had not been classified (D33E)25
was seen in eight (2.0%) patients and one (0.3%) control
individual. The seven variants not reported before were seen in
seven patients only. One previously reported nonsynonymous
SNP, I264V, is a common sequence variant and was found in
patients and controls at a similar frequency (Table 1). Alto-
gether, the nonsynonymous variants (excluding the common
I264V variant) were detected in a total of 41 (10.2%) patients
compared with 27 (7.2%) control subjects (P  0.1619; Fisher
exact test). However, owing to our data (Table 1) and to recent
WDR36 screenings reported by other groups,25–28 the nonsyn-
onymous variants L25P, A163V, H212P, A449T, and D658G are
rather addressed as polymorphisms due to frequent detection
in healthy subjects. Consequently, when these five putative
polymorphisms were excluded from our statistical analysis, the
remaining eight nonsynonymous amino acid alterations were
detected in 15 patients (3.7%) and 1 control subject (0.2%; P
0.0005).
Six synonymous amino acid changes, one of which was
novel (R430R), and 24 additional intronic variants were seen in
patients and controls at comparable frequency (Table 1). Based
on their positions we judged these synonymous changes and
the intronic variants unlikely to affect correct splicing and
therefore to be polymorphisms thus excluding them from
further analysis (Table 1).
In the group of 41 unrelated patients with glaucoma carry-
ing the nonsynonymous amino acid changes, we could not
detect a significant correlation between the presence of a
specific WDR36 variation (either defined as polymorphism or
putative disease-causing variant) and a particular clinical aspect
or diagnostic parameter (Table 2).
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DISCUSSION
We report the largest variation screening for WDR36 in pa-
tients with glaucoma to date. We identified 13 rare nonsynony-
mous amino acid variants, of which 7 were novel and 6 had
been described. Five of these described variants (L25P, A163V,
H212P, A449T and D658G) were found in similar frequencies
in patients with glaucoma and control subjects (6.5% and 69%,
respectively) and failed to cosegregate with the disease in their
respective families (data not shown). As glaucoma has an
extremely variable age of onset, we cannot exclude that in
some of these healthy subjects (n  26, age ranges from 62 to
83, mean age 69.9 5.6) glaucoma may develop later in life, or
it may never manifest in some patients. On the other hand, the
absence of a significant overall difference between patients and
controls questions the previous assumption19 that these vari-
ants inWDR36 can cause glaucoma. Studies in an Australian, an
Iowa and a French-Canadian population reported a single and
three WDR36 variants, respectively, to be at similar or even
higher frequency in controls,26–28 supporting a neutral role for
them.
Another recent study that screened a smaller cohort of 118
patients with glaucoma in the United States25 also reported
several families with three of these WDR36 variants that failed
to segregate with the disease. This differs from the initial report
of cosegregation in one family showing linkage to the GLC1G
locus. WhereasWDR36 is located at this locus, the data cannot
exclude the casual cosegregation in this family due to linkage
disequilibrium. Thus, another gene located in close proximity
at this locus could be the causative gene. This notion is sup-
ported by the increasing number of reports identifying families
linked to the GLC1G locus but lacking aWDR36 mutation29–31
and by a new study that maps the glaucoma locus GLC1M next
to GLG1G.32
TABLE 1. WDR36 Sequence Variants in Patients and Control Individuals
Exon/Intron Alleles Db SNPs AA Substitution Protein Domain Patients Controls
Nonsynonymous
1 c.74TC L25P* Unknown 8/399 2/376
1 c.91CA P31T Unknown 1/399 0/376
1 c.99CG D33E Unknown 8/399 1/376
1 c.290AG Y97C WD40 1/399 0/376
3 c.377GA D126N WD40 1/399 0/376
4 c.488CT A163V* WD40 7/399 5/376
5 c.635ATCC H212P* WD40 4/399 11/376
7 c.790AG rs11241095 I264V WD40 204/399 48/94
10 c.1207AG T403A WD40 1/399 0/376
10 c.1231CT H411Y WD40 1/399 0/376
10 c.1232AT H411L WD40 1/399 0/376
11 c.1345GA A449T† WD40 3/399 3/376
12 c.1460CG P487R WD40 1/399 0/376
17 c.1973AG D658G† WD40 4/399 5/376
Synonymous
3 c.402CT G134G WD40 6/399 14/376
3 c.423TC rs17132775 Y141Y WD40 2/399 0/376
5 c.591GA Q197Q WD40 3/399 2/376
11 c.1290TC R430R WD40 1/399 0/376
18 c.2142CG rs17624563 V714V None 53/307 13/94
19 c.2181AT rs13186912 V727V Utp21 172/307 52/94
Intronic
5UTR IVS0-75CT — — 195/399 218/376
5UTR IVS0-32TC — — 1/399 0/376
IVS1 IVS1-130CG rs17623144 — — 123/307 ND
IVS1 IVS1-38TA — — 1/307 ND
IVS2 IVS2-66TC — — 1/307 0/376
IVS3 IVS3-47GC — — 6/399 2/376
IVS4 IVS4-27AG — — 2/399 1/376
IVS5 IVS530CT rs10038177 — — 219/399 221/376
IVS6 IVS5-25CT — — 2/307 ND
IVS8 IVS836CT — — 1/307 ND
IVS9 IVS9-81TC — — 2/307 1/376
IVS12 IVS1290CT rs10043631 — — 287/399 284/376
IVS12 IVS12-39GA — — 1/307 ND
IVS13 IVS1389GA — — 145/307 ND
IVS13 IVS1391AG — — 1/307 ND
IVS16 IVS1641CT — — 6/307 ND
IVS16 IVS16-30AG rs17553936 — — 222/399 216/376
IVS21 IVS2160GC rs2290680 — — 52/307 ND
IVS21 IVS21-75GA — — 21/307 ND
IVS21 IVS21-23AG — — 11/307 ND
IVS21 IVS21-8TG rs10041326 — — 1/307 ND
IVS22 IVS22-65TC — — 1/307 ND
IVS23 IVS237AT — — 1/307 ND
IVS23 IVS2317AC — — 16/307 ND
ND, not determined.
* Previously designated as disease-susceptible.
† Previously designated as disease-causing.
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Seven rare variants were seen, each in one patient, but not
in any of the control individuals, whereas one variant (D33E)
was found in six patients and only one control subject 75 years
of age. Altogether these variants were found more frequently in
patients than in controls (3.7% and 0.2%, respectively). The
occurrence of different rare variants is characteristic of highly
heterogeneous diseases such as glaucoma, as rare mutations
have been also reported for MYOC. Moreover, since six of
eight of these mutations are located within a WD40 domain, it
is likely that their alterations directly interfere with the func-
tion of the protein. Validation as bona fide mutations would
require experimental verification in functional assays, which at
the moment are difficult to perform given the unknown func-
tion of WDR36.
In any case these rare variants would represent only a
minor cause of open-angle glaucoma. This conclusion is
FIGURE 1. Evolutionary conservation of nonsynonymous WDR36 amino acid variants and location on protein domain structure. (A) Multiple amino
acid sequence alignment shows evolutionary conservation of seven WDR36 variants among different species. Gray: residues affected by mutations.
(B) Our protein modeling predicts WDR36 to contain 14 WD40 repeats. (Structure prediction of WDR36 was performed by using the consensus
structure prediction available via the BioInfo Meta-Server, http://bioinfo.pl/meta/ BioInfoBank Institute, Poznan, Poland.) All eight putative
disease-causing variants identified in this study are shown (black) above the predicted domain organization. Six variants were located in the
proposed WD-40 repeats, whereas none was identified in the C-terminal region of the protein.
TABLE 2. Phenotypic Composition of Patients with WDR36 Variations
Missense
Mutations GLC Type
Age at
Diagnosis
(y)
Max IOP
(mmHg)
Optic Disc
(Jonas)
Mean Defect
(dB) Median
Corrected
Loss
Variance
(dB2)
Disc Area
(mm2)
Chamber
AngleMean SD Mean SD Mean SD Mean SD
L25P 5 POAG, 1 NTG,
2 JOAG
45.4 18 30 8.7 I, II, IV 7.65 (3.7–18.6) 14.1 10.1 2.4 0.6 3–4
P31T 1 POAG 77 28 V (blind) 15.8 — 3
D33E 5 POAG, 2 NTG,
1 JOAG
45.8 14.2 29.3 5.3 II, III, IV 11.1 (5.2–14.7) 68.5 31.3 2.7 0.6 3–4
Y97C 1 POAG 53 25 II 6.45 61.7 4
D126N 1 NTG 65 21 I
A163V 7 POAG 55.6 8.6 29.5 4.8 II, III, IV 16.1 (2.0–20.8) 54.1 18.2 2.4 0.6 3–4
H212P 3 POAG, 1 NTG 64.7 10.5 30.5 10.7 II, III, IV 10.5 (4.2–17.1) 56.5 52.4 3.2 1.7 2–4
T403A 1 JOAG 29 40 V (blind) 13.8 86.3 2.5 4
H411Y 1 POAG 61 26 IV 3.8 (4.3–2.5) 37.3 19.7 2.8 4
H411L 1 POAG 66 22 II 3.5
A449T 2 POAG, 1 NTG 53.6 12.6 26.8 16 0, I, II, V 5.3 (1.9–11.8) 29.0 38.0 3.0 0.2 4
P487R 1 POAG 60 28 III 12.7 135.8 2.99 3
D658G 2 POAG, 1 NTG,
1 JOAG
43 22.6 37.7 21.4 II, III, IV 13.9 (3.6–24.2) 79.2 9.9 2.5 2.4 3–4
The width of the chamber angle is according to Shaffer. Missing data were not available for evaluation.
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supported by the recent report by Weisschuh et al.,33 who
reported a frequency of 3.6% (4/112) of rare mutation car-
riers in a smaller cohort of 112 German patients with NTG,
which is very similar to the frequency found in our NTG
subgroup (3.7%, 3/82; Table 2, and the Material and Methods
section). In addition, our data suggest that these variants in
WDR36 are not characteristic of any particular group of
patients with glaucoma and none seems to correlate with a
particular clinical aspect or disease severity (Table 2). For
example, amino acid change D33E was found in eight pa-
tients with age at onset ranging from 14 to 72 years and both
normal and high ocular tension (20–40 mm Hg). Overall, in
patients carrying a variant, the age of onset ranged from
juvenile (14 years) to late adulthood (77 years), and the
maximum intraocular ocular pressures varied from 16 to 50
mm Hg, thus indicating that WDR36 variants are equally
present in all three types of open-angle glaucoma (4.2%
JOAG, 3.7% NTG and 3.7% POAG patients, Table 2). The
degree of disc atrophy ranged from mild cupping to pro-
gressed loss of neuroretinal rim of the optic disc, resulting in
wide variety of mild and severe visual field loss. Also the disc
size ranged from small discs with 1.6 mm2 to large discs with
5.0 mm2. The chamber angle in the eye was wide open in all
patients.34 Thus, we conclude that WDR36 variations are
not restricted to a specific type of glaucoma.
In summary, our findings indicate that sequence variants in
WDR36 are only rare causes of unrelated glaucoma in German
population. Clearly, investigation of additional families and
populations, extensive functional studies, as well identification
of WDR36 binding partners are essential for further under-
standing the role of WDR36 in the pathophysiology of glau-
coma.
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